Get the Stockscreener App
13.13
0.00%
0.00
After Hours:
13.13
Elanco Animal Health Inc stock is traded at $13.13, with a volume of 3.94M.
It is up +0.00% in the last 24 hours and up +5.80% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$13.13
Open:
$13.2
24h Volume:
3.94M
Relative Volume:
0.89
Market Cap:
$6.66B
Revenue:
$4.49B
Net Income/Loss:
$-1.26B
P/E Ratio:
-65.65
EPS:
-0.2
Net Cash Flow:
$425.00M
1W Performance:
-2.31%
1M Performance:
+5.80%
6M Performance:
-21.80%
1Y Performance:
+8.96%
1-Day Range:
$13.12
$13.48
1-Week Range:
$12.83
$13.65
52-Week Range:
$11.40
$18.80
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
13.13 | 6.66B | 4.49B | -1.26B | 425.00M | -0.20 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health Incorporated Investors: Please contact the Portnoy Law Firm to recover your losses. December 6, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
ELAN (Elanco Animal Health) EBITDA : $1,337 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health (MEX:ELAN) Other Stockholders Equity : MXN0 Mil (As of Sep. 2024) - GuruFocus.com
ELAN (Elanco Animal Health) EBIT per Share : $1.34 (TTM As of Sep. 2024) - GuruFocus.com
Elanco's Global Day of Purpose: 11,000+ Volunteer Hours, 100,000 Meals Packed Worldwide | ELAN Stock News - StockTitan
Elanco Celebrates Global Day of Purpose - ReportAlert.info
ELAN (Elanco Animal Health) Interest Expense : $-256 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health Incorporated (ELAN): An Oversold Healthcare Stock to Invest In Now - Yahoo Finance
ELAN (Elanco Animal Health) Other Current Receivables : $64 Mil (As of Sep. 2024) - GuruFocus.com
ELAN (Elanco Animal Health) Receivables Turnover : 1.12 (As of Sep. 2024) - GuruFocus.com
ELAN (Elanco Animal Health) Earnings Yield % : 2.99% (As of Nov. 26, 2024) - GuruFocus.com
Investors who lost money on Elanco Animal Health Incorporated(ELAN) should contact Levi & Korsinsky about pending Class ActionELAN - PR Newswire
ELAN (Elanco Animal Health) 50-Day SMA : $13.68 (As of Nov. 26, 2024) - GuruFocus.com
ELAN (Elanco Animal Health) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
ELAN (Elanco Animal Health) Debt-to-EBITDA : 1.38 (As of Sep. 2024) - GuruFocus.com
ELAN Class Action News: Robbins LLP Reminds Investors of the Quickly Approaching Lead Plaintiff Deadline in the Elanco Animal Health Incorporated Class Action - The Malaysian Reserve
2024-11-26 | Lost Money on Elanco Animal Health Incorporated(ELAN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky | NYSE:ELAN | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming DeadlinesELAN - PR Newswire
Elanco to Participate in the Upcoming Investor Conferences - PR Newswire
ELAN (Elanco Animal Health) Change In Payables And Accrued Expense : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
B. Metzler seel. Sohn & Co. Holding AG Purchases Shares of 38,922 Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
ELAN (Elanco Animal Health) Cash Flow for Lease Financing : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
ELAN DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
2024-11-24 | Shareholders of Elanco Animal Health Incorporated Should Contact Levi & Korsinsky Before December 6, 2024 to Discuss Your RightsELAN | NYSE:ELAN | Press Release - Stockhouse Publishing
Elanco (ELAN) Faces Federal Lawsuit Over Alleged Misrepresentation of Zenrelia's Safety Profile – Hagens Berman - GlobeNewswire
ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit - PR Newswire
Landscape Capital Management L.L.C. Reduces Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Jennison Associates LLC Has $15.87 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
ELAN CLASS ACTION NOTICE: BFA Law Alerts Elanco Animal Health Investors the Company has been Sued for Securities Fraud and Urges You to Contact the Firm - Newsfile
ELAN IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Elanco Animal Health Incorporated(ELAN) of a Class Action Lawsuit and an Upcoming Deadline - The Malaysian Reserve
ELAN Investors Have Opportunity to Lead Elanco Animal Health Inc - GuruFocus.com
Elanco (ELAN) Hit with Investor Lawsuit Over New Drug – Hagens Berman - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - The Malaysian Reserve
Primecap Management Co. CA Has $772.33 Million Holdings in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Receives $17.14 Consensus PT from Analysts - MarketBeat
Veterinary Medicine Market Future Business Opportunities 2024-2031 | Ceva, Zoetis, Elanco, Chanelle Pharma Group - openPR
Just in time for Thanksgiving, SEC charges Elanco with undisclosed stuffing—channel stuffing, that is - JD Supra
Silent & Spreading: The Tapeworm Story Every Pet Owner Needs To Hear - ReportAlert.info
2024-11-20 | Shareholders that lost money on Elanco Animal Health Incorporated (ELAN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NYSE:ELAN | Press Release - Stockhouse Publishing
Merck to buy Elanco’s aqua business for $1.3B in cash - MSN
Companion Animal Arthritis Market Innovations in Treatment - openPR
Phocas Financial Corp. Sells 184,554 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Bragar Eagel & Squire Files Class Action Against Elanco Animal Health Incorporated for Securities Fraud - Lawyer Monthly Magazine
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):